Methyprylon

Methyprylon

File:Methyprylon.png
Clinical data
ATC code	N05CE02 (WHO)
Pharmacokinetic data
Protein binding	60%
Elimination half-life	6-16 hours
Identifiers
IUPAC name 3,3-diethyl-5-methyl-piperidine-2,4-dione
CAS Number	125-64-4
PubChem CID	4162
DrugBank	APRD00734
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H17NO2
Molar mass	183.248 g/mol

WikiDoc Resources for Methyprylon
Articles
Most recent articles on Methyprylon Most cited articles on Methyprylon Review articles on Methyprylon Articles on Methyprylon in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Methyprylon Images of Methyprylon Photos of Methyprylon Podcasts & MP3s on Methyprylon Videos on Methyprylon
Evidence Based Medicine
Cochrane Collaboration on Methyprylon Bandolier on Methyprylon TRIP on Methyprylon
Clinical Trials
Ongoing Trials on Methyprylon at Clinical Trials.gov Trial results on Methyprylon Clinical Trials on Methyprylon at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Methyprylon NICE Guidance on Methyprylon NHS PRODIGY Guidance FDA on Methyprylon CDC on Methyprylon
Books
Books on Methyprylon
News
Methyprylon in the news Be alerted to news on Methyprylon News trends on Methyprylon
Commentary
Blogs on Methyprylon
Definitions
Definitions of Methyprylon
Patient Resources / Community
Patient resources on Methyprylon Discussion groups on Methyprylon Patient Handouts on Methyprylon Directions to Hospitals Treating Methyprylon Risk calculators and risk factors for Methyprylon
Healthcare Provider Resources
Symptoms of Methyprylon Causes & Risk Factors for Methyprylon Diagnostic studies for Methyprylon Treatment of Methyprylon
Continuing Medical Education (CME)
CME Programs on Methyprylon
International
Methyprylon en Espanol Methyprylon en Francais
Business
Methyprylon in the Marketplace Patents on Methyprylon
Experimental / Informatics
List of terms related to Methyprylon

Methyprylon is a sedative of the piperidinedione derivative family. This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with less side effects, such as benzodiazepines. Methyprylon was withdrawn from the US market in June 1965 and the Canadian market in September 1990.

Side effects can include: Skin rash, fever, depression, ulcers or sores in mouth or throat, unusual bleeding or bruising, confusion, fast heartbeat, respiratory depression, swelling of feet or lower legs, dizziness, drowsiness, headache, double vision, clumsiness, constipation, diarrhea, nausea, vomiting, unusual weakness

External links

• Contos D, Dixon K, Guthrie R, Gerber N, Mays D (1991). "Nonlinear elimination of methyprylon (noludar) in an overdosed patient: correlation of clinical effects with plasma concentration". J Pharm Sci. 80 (8): 768–71. PMID 1686463.CS1 maint: Multiple names: authors list (link)
• Gwilt P, Pankaskie M, Thornburg J, Zustiak R, Shoenthal D (1985). "Pharmacokinetics of methyprylon following a single oral dose". J Pharm Sci. 74 (9): 1001–3. PMID 2866242.CS1 maint: Multiple names: authors list (link)
• Lomen P, Linet O (1976). "Hypnotic efficacy of triazolam and methyprylon ininsomniac in-patients". J Int Med Res. 4 (1): 55–8. PMID 16792.